Introduction
============

Malaria is a serious and sometimes fatal disease. Early and accurate detection of malaria infection is important to reduce its associated morbidity and mortality \[[@B1]\]. The gold standard for the detection of malaria infection is microscopic examination, and the most reliable method is genetic examination by polymerase chain reaction (PCR) or deoxyribonucleic acid (DNA) sequencing \[[@B2]\]. Rapid diagnostic tests (RDTs) for malaria are widely used as a substitute for microscopic examination because of their good accessibility. RDTs detect different target antigens such as histidine rich protein 2 (HRP2) \[[@B3]--[@B5]\] or *Plasmodium falciparum*-specific lactate dehydrogenase (PfLDH) \[[@B5]--[@B7]\] for *Plasmodium falciparum*, *Plasmodium vivax*-specific lactate dehydrogenase (Pv-pLDH) \[[@B8]\], and aldolase \[[@B3], [@B4], [@B6]\] or plasmodium lactate dehydrogenase (pLDH) \[[@B5], [@B7], [@B9], [@B10]\] for *P. vivax*, *Plasmodium ovale* and *Plasmodium malariae*.

Although the usefulness of RDTs for *P. falciparum* is well recognized \[[@B11], [@B12]\], RDTs are often ineffective in detecting other malaria species. Moreover, very few reports have described the performance of RDT in travellers particularly regarding *P. ovale* malaria. For returned travellers in non-endemic settings, it is sometimes difficult to distinguish *P. vivax* malaria from *P. ovale* malaria without PCR because the clinical and microscopic features are very similar. We investigated the performance of RDTs for the detection of *P. ovale* malaria in Japanese travellers by comparing their performance with that of RDTs for *P. vivax* malaria.

Methods
=======

This study was a retrospective cohort study on Japanese travellers diagnosed with malaria at the National Center for Global Health and Medicine (NCGM) between January 2004 and June 2013. Malaria cases were diagnosed by microscopic examination using initial blood samples at the NCGM Research Institute. Parasite concentration (parasitemia) was calculated by counting the number of parasites per 200,000 red blood cells in a thin blood smear. The RDTs used in our study were Binax NOW Malaria (Binax Inc., Scarborough, Maine, USA) (BN), which detects histidine-rich protein for the identification of falciparum malaria and plasmodium aldolase for the identification of non-falciparum malaria, and SD Malaria Antigen Pf/Pan (Standard Diagnostics Inc., Korea) (SDMA), which detects plasmodium lactic acid dehydrogenase (pLDH) for the identification of all four human malaria parasites. BN could not be obtained in our institute between July 2008 and May 2010, which made it necessary to use SDMA during the period instead of BN. RDTs were performed once for each sample. Concerning the line intensity reading, a test line strong enough to read was deemed positive. Microscopic examination and RDTs were immediately conducted after taking blood tests, and RDTs were conducted in accordance with the manufacturer's instructions.

When parasites were detected microscopically, the species was confirmed by nested PCR. The small subunit rRNA (SSU rRNA) from the nuclear DNA of the four human malaria parasite species were amplified by nested PCR using respective primer sets for *P. falciparum*, *P. vivax*, *P. ovale* and *P. malariae*. The nested PCR condition and the species specific primers followed Kimura's method \[[@B13]\]. To detect *P. knowlesi*DNA, the SSU rRNA from nuclear DNA and cytochrome *b* from mitochondrial DNA of *P. knowlesi* were amplified by nested PCR. The sequences of the PCR products were determined using an ABI 3130xl Genetic Analyzer (Applied Biosystems, CA, USA) after TA cloning. *P. knowlesi*specific primer set, the condition of the nested PCR and DNA sequencing were the same as those used in our previous study \[[@B14]\].

Statistical analysis was performed by Stata ver.11 (Stata Corp, Texas, USA). The chi-square and Fisher's exact probability tests were used to compare the characteristics of *P. ovale* malaria and *P. vivax* malaria for dichotomous variables, and the Student's *t*-test was used to compare continuous variables. A difference of P \< 0.05 was considered significant.

Results
=======

Microscopic examination was performed for diagnosis in all of the malaria cases. A total of 153 cases of malaria were observed between January 2004 and June 2013, 113 of which were found among Japanese travellers. Of the latter, there were 78 cases of *P. falciparum* malaria (including 1 case of co-infection with *P. malariae* malaria and 1 case of co-infection with *P. vivax* malaria confirmed by PCR), 22 cases of *P. vivax* malaria (including 1 case of co-infected with *P. falciparum* malaria confirmed by PCR), 11 cases of *P. ovale* malaria, 3 cases of *P. malariae* malaria, and 1 case of *P. knowlesi* malaria. RDTs were performed in 67, 21, 10, 2, 1 and 2 cases among the mono-infection cases of *P. falciparum* malaria, *P. vivax* malaria, *P. ovale* malaria, *P. malariae* malaria, *P. knowlesi* malaria and co-infection cases, respectively. The cases confirmed by PCR were 11, 19, 10, 3 and 1 cases in *P. falciparum* malaria, *P. vivax* malaria, *P. ovale* malaria, *P. malariae* malaria and *P. knowlesi* malaria, respectively (Table [1](#T1){ref-type="table"}).

We focused on a comparison of *P. ovale* malaria mono-infection cases and *P. vivax* malaria mono-infection cases. There were 10 cases of *P. ovale* malaria (mean age, 27.8 years; male-to-female ratio, 2.3:1) and 18 cases of *P. vivax* (mean age, 29.8 years; male-to-female ratio, 2.6:1). These patients constituted the final study population. The results of RDTs were evaluated for 9 patients with *P. ovale* malaria and 17 patients with *P. vivax* malaria (excluding 1 co-infected case).

Among the 18 cases of *P. vivax* malaria, 13 (72.2%) had been infected in Asia, 4 (22.2%) in South America, and 1 (5.6%) in Africa (Republic of Rwanda) (Table [2](#T2){ref-type="table"}). All of the 10 cases of *P. ovale* malaria had been infected in Africa (Table [3](#T3){ref-type="table"}). The average parasitemia in the cases of *P. ovale* malaria was significantly lower than that in *P. vivax* malaria (P = 0.002). The sensitivity of RDTs for *P. ovale* malaria was also significantly lower than that for *P. vivax* malaria (P \< 0.001). The sensitivity of SDMA for *P. vivax* malaria and *P. ovale* malaria was 100% (7/7) and 50% (2/4), respectively. The sensitivity of BN for *P. vivax* malaria was 90.0% (9/10), but it was ineffective in detecting the cases of *P. ovale* malaria (0/5; Table [4](#T4){ref-type="table"}). There were only 3 cases of *P. malariae* malaria, one of which showed co-infection with *P. falciparum*. The other 2 cases of *P. malariae* malaria were mono-infection of *P. malariae*. In the mono-infection cases, one case of *P. malariae* malaria showed a positive line detecting pLDH of SDMA while the other case showed a positive line detecting aldolase of BN.

Discussion
==========

RDTs are generally useful for diagnosing malaria infection \[[@B3]--[@B5]\]. However, the sensitivity of RDTs depends upon the species of malaria parasite. The highest sensitivity was observed for *P. falciparum* malaria (78.8--99.1%) \[[@B5], [@B11], [@B15]--[@B18]\], followed by *P. vivax* malaria (77.6--96%), *P. ovale* malaria (18.4--80.0%), and *P. malariae* malaria (21.4--47.0%) \[[@B3]--[@B5], [@B19], [@B20]\]. For non-falciparum malaria, RDT sensitivity was particularly low for *P. ovale* and *P. malariae*, a finding that may be attributable to the low parasitemia \[[@B3]--[@B5]\], the difference in targeted antigens \[[@B6], [@B9], [@B10]\], or the genetic variability between the infected parasites \[[@B21], [@B22]\].

Low parasitemia was associated with false-negative results from the RDTs regardless of malaria species \[[@B4], [@B5]\]. Moreover, since reinfection and semi-immune status generally cause low parasitemia \[[@B23]\], those influences need to be eliminated. Travellers who visiting families and relatives and expatriates living in malaria endemic areas were excluded from our study because they were at a higher risk of reinfection. The parasitemia in *P. ovale* malaria was consequently as low as that in immune patients and was significantly lower than that in *P. vivax* malaria. This finding, along with those in previous reports \[[@B23]\], suggests that *P. ovale* malaria presents with low parasitemia even in non-immune travellers, which may result in false-negative results from the RDTs.

As mentioned above, *P. malariae* and *P. ovale* malaria may be difficult to diagnose by RDTs due to the low parasitemia \[[@B7], [@B8], [@B11]\]. Recently, Houzé et al. \[[@B24]\] reported that the new RDT, Clearview, has improved sensitivity for *P. malariae* malaria but that the sensitivity for *P. ovale* malaria was not improved. Moreover, even a case of *P. ovale* malaria with relatively high parasitemia (21,150 parasites/μL) resulted in a false-negative RDT result in their study, implying some reason for false-negative results other than low parasitemia in *P. ovale* malaria. The difference in target antigens from parasites, such as HRP2 and PfLDH for *P. falciparum* or pLDH and aldolase for pan-malaria species, can also influence the sensitivity of RDTs \[[@B6]\]. Detecting *P. ovale* and *P. vivax*, two RDTs (BN for aldolase detection and SDMA for pLDH detection) were used in our study. SDMA showed relatively good sensitivity for both *P. vivax* and *P. ovale* as compared to BN, probably because pLDH-based RDTs generally perform better than aldolase-based RDTs \[[@B20]\]. Bigaillon et al. \[[@B6]\] also reported the ineffectiveness of BN in detecting *P. ovale* malaria, which they suggested was due to low aldolase production by *P. ovale* malaria \[[@B10]\]. Aldolase-based RDTs generally show low sensitivity not only for *P. ovale* malaria but also for other types of malaria \[[@B9]\], but low sensitivity was also observed for pLDH-based RDTs \[[@B10]--[@B12], [@B16], [@B17], [@B24]\].

Although the genetic variability of HRP2 was related to the low sensitivity of RDTs for *P. falciparum* malaria \[[@B21]\], it was reported that the genetic variability of pLDH \[[@B22]\] and aldolase \[[@B25], [@B26]\] did not explain the relatively poor performance of RDTs for the detection of *P. falciparum*, *P. vivax*, and *P. malariae*. Talman et al. \[[@B22]\] reported that *P. ovale* exhibited three different types of amino acid sequence (named O1, O2 and O3), whichmay contribute to the relatively poor detection of *P. ovale*. The sensitivity of RDTs is still insufficient for accurate diagnosis of *P. ovale* malaria regardless of the type of antigens. Therefore, microscopic examination is preferable for the definitive diagnosis of *P. ovale* malaria.

The sensitivity of RDTs was not high enough to accurately diagnose *P. ovale* malaria in Japanese travellers who were never infected with malaria previously. Thus, microscopic examination is required to ensure that *P. ovale* malaria is not overlooked.
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###### 

The characteristics of 153 malaria cases from microscopic analysis

                                      Japanese Travellers   RDTs   PCR   
  ----------------------------------- --------------------- ------ ----- ----
  Total                               153                   113    103   42
   Mono-Infections                                                       
    *P. falciparum*                   76                    67     9     
    *P. vivax*                        21                    21     18    
    *P. ovale*                        11                    10     10    
    *P. malariae*                     2                     2      2     
    *P. knowlesi*                     1                     1      1     
   Co-Infections                                                         
    *P. falciparum* + *P. malariae*   1                     1      1     
    *P. falciparum* + *P. vivax*      1                     1      1     

###### 

The characteristics of the cases of *P. vivax* malaria

  ----------------------------------------------------------------------------------------------------------------------
  No.   Year   Country                               Type of RDTs   Result of RDTs\       Parasitemia\   Result of PCR
                                                                    (T1/T2, P.f, Pan)\*   (%)            
  ----- ------ ------------------------------------- -------------- --------------------- -------------- ---------------
  1     2004   Banuatu                               BN             +/+                   0.15           Pf, Pv

  2     2006   Rwanda                                BN             −/+                   0.18           Pv

  3     2007   Indonesia                             BN             −/+                   0.20           Pv

  4     2007   Indonesia                             SDMA           −/+                   ND             Pv

  5     2007   PNG                                   BN             −/+                   0.20           Pv

  6     2007   Malaysia                              BN             −/−                   0.005          Pv

  7     2007   Brasil                                BN             −/+                   0.79           Pv

  8     2008   India                                 SDMA           −/+                   0.06           Pv

  9     2008   India                                 SDMA           −/+                   0.40           Pv

  10    2009   PNG                                   SDMA           −/+                   0.13           Pv

  11    2009   Equador                               SDMA           −/+                   0.15           Pv

  12    2009   Thailanda, India, Nepal, Bangladesh   BN             −/+                   0.06           Pv

  13    2009   French Guiana                         SDMA           −/+                   0.34           Pv

  14    2010   Sudan                                 SDMA           −/+                   0.22           Pv

  15    2010   Brasil                                BN             −/+                   0.10           Pv

  16    2010   Indonesia                             BN             −/+                   0.09           Pv

  17    2010   India                                 BN             −/+                   0.33           Pv

  18    2011   PNG                                   BN             −/+                   0.02           Pv
  ----------------------------------------------------------------------------------------------------------------------

PNG: Papua New Guinea; BN: Binax NOW^®^ malaria; SDMA: SD malaria antigen^®^; ND: not described; Pf: *Plasmodium falciparum*; Pv: *Plasmodium vivax*.

\*T1: the positive band of Histidine rich protein 2 and T2: the positive band of aldolase for BN, P.f: the positive band of *Plasmodiun falciparum* lactate dehydrogenase (LDH) and Pan: the positive band of Plasmodium LDH, for SDMA.

###### 

The characteristics of the cases of *P. ovale* malaria

  --------------------------------------------------------------------------------
  No.   Year   Country   Type of RDTs   Result of RDTs\       Parasitemia\   PCR
                                        (T1/T2, P.f, Pan)\*   (%)            
  ----- ------ --------- -------------- --------------------- -------------- -----
  1     2004   Ghana     BN             −/−                   0.030          Po

  2     2005   Senegal   BN             −/−                   0.060          Po

  3     2006   Uganda    ND             ND                    0.040          Po

  4     2007   Uganda    BN             −/−                   0.040          Po

  5     2008   Uganda    SDMA           −/−                   0.001          Po

  6     2009   Ghana     SDMA           −/+                   0.080          Po

  7     2010   Uganda    SDMA           −/+                   0.004          Po

  8     2010   Ghana     SDMA           −/−                   0.012          Po

  9     2012   Uganda    BN             −/−                   0.042          Po

  10    2013   Uganda    BN             −/−                   0.003          Po
  --------------------------------------------------------------------------------

BN: Binax NOW^®^ malaria; SDMA: SD malaria antigen^®^; M: male; F: female; ND: not described, Po: *Plasmodium ovale*.

\*T1: the positive band of Histidine rich protein 2 and T2: the positive band of aldolase for BN, P.f: the positive band of *Plasmodiun falciparum* lactate dehydrogenase (LDH) and Pan: the positive band of Plasmodium LDH, for SDMA.

###### 

The comparison between *P. vivax* malaria cases and *P. ovale* malaria cases

                            *P. vivax* malaria   *P. ovale* malaria   P value
  ------------------------- -------------------- -------------------- ----------
  Number of patients        18                   10                   
  Age (mean ± SD)           29.8 ± 12.0          27.8 ± 7.0           0.326
  Sex (male)                13                   7                    0.900
  Areas to travel                                                     
   Africa                   1                    10                   
   Asia, Oceania            13                   0                    \< 0.001
   South America            4                    0                    
  Average parasitemia (%)   0.229                0.031                0.002
  Positive by RDTs (%)      16/17 (94.1)         2/9 (22.2)           \< 0.001
  BN (%)                    9/10 (90.0)          0/5 (0)              \< 0.001
  SDMA (%)                  7/7 (100)            2/4 (50.0)           0.039

The data are presented as number of patients, unless otherwise specified.

*P. vivax*: *Plasmodium vivax*; *P. ovale*: *Plasmodium ovale*; RDT: rapid diagnostic test; BN: Binax NOW^®^ malaria; SDMA: SD malaria antigen^®^
